IXICO to Participate in SENSE-Cog, a Pan European Consortium

March 9, 2016

Download full press release

09 March 2016, IXICO plc (Ticker: IXI) (‘IXICO’ or the ‘Company’), the brain health company, is pleased to announce its participation in SENSE-Cog, a European consortium (‘SENSE-Cog’) researching the combined impact of dementia, hearing and vision impairment in the elderly. The project aims to define the scope of the problem and develop new tools to help the effective diagnosis and treatment of the dual or triple impairment in order to improve quality of life and optimise health and social care budgets across Europe. 

IXICO will receive funding to provide the SENSE-Cog e-screen, a digital application incorporating cognitive, mental health, vision and auditory tests which will be performed on elderly Europeans in a wide variety of settings including the home, community pharmacies and primary care offices. Seven in ten Europeans over the age of 65 suffer from either sight or hearing problems and over two thirds suffer from depression or dementia.  Together these conditions have a far greater impact than on a discrete, individual basis. 

Professor Derek Hill, Chief Executive of IXICO, commented: “We are delighted to be working alongside partners to trial novel and inclusive approaches to support people living with these dual or triple impairments. Our participation in this project reiterates our expertise in the burgeoning digital health space. SENSE-Cog is seeking to address combined sensory, cognitive and mental impairments to support swift interventions, prevent deterioration and limit negative impacts.”

The five year SENSE-Cog project has been funded by the European Commission Horizon 2020 research programme. Led by the University of Manchester, the project is a consortium of 17 academic and industrial partners. 

IXICO plc   
Derek Hill, CEO    
Susan Lowther, CFO    

 +44 20 3763 7499
Peel Hunt LLP (Nominated Adviser and Broker)    

James Steel / Oliver Jackson    

+44 20 7418 8900
Daniel Stewart & Company (Joint Broker)    
Martin Lampshire / David Coffman    

+44 207 776 6550
FTI Consulting Limited (Investor Relations)    
Simon Conway / Mo Noonan / Matthew Moss    

+44 20 3727 1000

Notes to Editors

IXICO’s innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com